KRAS and neoplasm: In the KRAS-mutant lung cancer model, blockade of both PD-1 and helix-loop-helix transcription factor inhibitor of differentiation 1 knock out significantly enhances the amount of CD8+ T cells as well as the expression of PD-L1, which impairs the tumor growth and increases the survival[126].